Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) described as a ‘major milestone’ the green light for a human challenge study that will assess the potential of its treatment for severe influenza.
Researchers will formally commence the trial of POLB 001 later this week (July 22) with a first data readout expected in the fourth quarter.
After that, the group will look for early monetisation opportunities in the form of partnerships and licensing agreements.
Success would also pave the way for potential applications beyond severe flu, Poolbeg said.
Chief executive Jeremy Skillington explained: “The unique mode of action of POLB 001 to reduce hyperinflammatory response in the body means that it is agnostic to the strain of virus and has the potential to expand to other disease indications and as such, could provide further opportunities to create significant value beyond severe influenza for the company and our shareholders."